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using the survey results and findings from the literature: cost of travel to receive 
healthcare (£780), household expenses (£136), cost of moving home (£65) and lost 
accommodation costs (£214). ConClusions: Patient survey results showed that 
aHUS has a substantial economic burden to patients, their carers and society. The 
total economic burden from lost productivity of patients, carers and out-of-pocket 
expenses was estimated to be £9,243 per aHUS patient per year.
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objeCtives: In the United States (US), the 1983 Orphan Drug Act (ODA) established 
incentives for the development of drugs that treat rare or orphan diseases (defined 
as diseases affecting < 200,000 Americans). Health Canada is currently developing 
an orphan drug framework (for diseases affecting ~5 in 10,000 Canadians). This study 
measured total annual expenditures of orphan drugs in the US and Canada (2007-
13) and estimated future (2014-18) orphan drug expenditures. Methods: Branded, 
orphan drugs approved by the US Food and Drug Administration (FDA) between 
1983-2013 were identified (N= 356). The Canadian analysis only included US orphan 
drugs with the same orphan indication(s) approved in Canada. Adjustment via dis-
ease factoring was applied to products with multiple indications (both orphan and 
non-orphan) using available data sources to isolate orphan-indication sales only. 
The IMS MIDAS database was used to assess total orphan drug expenditures, calcu-
lated annually from 2007-2013 and evaluated as a proportion of total annual phar-
maceutical drug expenditures (all reported in 2014 US dollars). Results: Between 
2007-2013, expenditures were measured for a final N= 316 and N= 147 orphan 
drugs in the US and Canada, respectively. In the US, total orphan drug expendi-
tures accounted for $15.0-$30.0 billion in 2007-13, representing 4.8-8.9% of total U.S. 
pharmaceutical expenditures, respectively. In Canada, orphan drug expenditures 
totaled $557.7-$1,005.8 million in 2007-13, representing 3.3-5.6% of total Canadian 
pharmaceutical expenditures, respectively. Future trend analysis (2014-18) suggests 
a slowing down in growth of orphan drug expenditures. ConClusions: While the 
number of available orphan drugs and associated expenditures increased over time, 
these drugs benefit many people with previously underserved rare conditions. From 
a societal perspective, the overall budget impact of orphan drugs is small and has 
remained fairly stable relative to total pharmaceutical expenditures. Concerns that 
growth in orphan drug expenditures may lead to unsustainable drug expenditures 
do not appear to be justified.
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objeCtives: The development of inhibitors is the most challenging complication of 
hemophilia treatment. Bypassing agents (i.e. aPCC and rFVIIa) remain the therapy 
of choice but account for a significant proportion of treatment cost. This study 
aims to compare the cost-effectiveness of aPCC vs. rFVIIa in on-demand treat-
ment from the Brazilian public health system perspective. Methods: A literature 
based cost model was developed based on utilization and efficacy (evaluated at 2, 
6, 12, 24, 36 and 48 hours after infusion) data from the FENOC (head-to-head) trial 
which investigated the equivalency of the clinical efficacy of aPCC and rFVIIa in 
on-demand treatment. The median (range) treatment dose was 84.6 (51.5-100) U/kg 
and 212.5 (98.6-261.8) µg/kg for aPCC and rFVIIa, respectively. Hemostatic efficacy 
ranged from 75% to 97.6% for aPCC and 60.4% to 85.4% for rFVIIa. Bleed resolution 
rate also ranged from 53.2% to 95.1% for aPCC and 38.3% to 92.7% for rFVIIa. Cost 
analysis was limited to drug costs and prices were obtained from the 2014 Brazilian 
Official Diary: U$0.71/U and U$0.64/µg for aPCC and rFVIIa, respectively. One-way 
sensitivity analyses were performed to determine model robustness when dose and 
price were varied by ±25%. Results: The cost/kg per on-demand bleed treatment 
was 55.9% lower for aPCC compared to rFVIIa. The cost/kg per treatment efficacy 
was 64% to 79% lower for aPCC compared to rFVIIa. Similarly, cost/kg per resolved 
bleed was 68% to 81% lower for aPCC compared to rFVIIa. Results remained robust 
for all one-way sensitivity analyses conducted. Given, an estimated total inhibitor 
population of 684 in Brazil, total saving with aPCC can vary from U$13.2-U$53.2 mil-
lion depending on market share. ConClusions: aPCC was the dominant therapy 
in on-demand treatment. Using the current Brazilian prices, for each bleed treated 
with rFVIIa about 2.3 bleeds could be treated with aPCC at comparable cost.
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objeCtives: Treatment of Cystic Fibrosis (CF) as rare disease is generally perceived 
as highly expensive, but we did not have more specific national or local costs data. 
Since patients are on lifelong treatment we tried to analyzed direct costs associated 
with CF in single center. Methods: We analyze direct costs associated with treat-
ment management of patients with CF in selected center in Slovakia from 2009 till 
2013. We reviewed 182 adult patients regularly visiting CF centrum. We distributed 
patients according to age that is closely connected with CF prognosis. We included: 
treatment costs, healthcare procedures, medical devices and hospitalization costs. 
We used perspective of healthcare provider. We chose cost-of-illness, prevalence-
based approach and compared costs based on time/year, gender, age and type of 
procedure. Results: We have found that adult patients with CF between age 30 and 
35 (21 patients) consumed most resources from 2009 till 2012, but most significantly 
objeCtives: BTcP is associated with a number of problematic physical, psycholog-
ical/emotional and social complications which themselves are not only a relevant 
source of additional morbidity in these patients, but are also responsible for sig-
nificant economic implications, for the patient, their relatives, for the healthcare 
system and society. Methods: We performed a systematic literature search of 
PubMed electronic database through December 2014 and February 2015. The key 
words included “breakthrough cancer pain” and “cost effectiveness” or “econom-
ics” or “pharmacoeconomic,” and MeSH terms included “breakthrough pain” and 
“neoplasms”, or “economics” or “cost-benefit analysis” . There were no language 
or study design restrictions. A total of 20 articles were identified. Among the 10 
included studies, there were two quality improvement projects, two survey studies, 
three decision-analytic models, one literature review, two pharmacoeconomics 
studies and one health economic framework. Results: BTcP is associated with 
increased medical costs: direct medical costs, indirect costs, intangible cost. Direct 
medical costs might include hospital charges, cost of analgesics and other medica-
tions, radiotherapy, surgery, and clinician time; direct non-medical costs might 
include the cost of gas to drive to the clinic, parking during a clinic visit, highway 
tolls, overnight lodging for family/caregivers, meals for caregivers. Intangible 
costs include the patient’s pain, suffering, depression, anxiety, loss of sleep, 
and fatigue, as well as the family’s and/or caregiver’s distress. ConClusions: 
Additional studies are needed to evaluate quality-of-life improvements and the 
cost-effectiveness of more systematic analgesic treatments for BTcP. By delineat-
ing all the factors describing the impact of BTcP on patients, providers, and society, 
a comprehensive health economic model will improve clinical decision making, 
optimize outcomes, and enhance satisfaction with the processes of care across all 
stakeholder levels. In the case of HTA in breakthrough cancer pain, ethical evalu-
ations appear to be the most important assessment focus among the considered 
ones.
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objeCtives: Familial Mediterranean Fever disease (FMF) is an autosomal reces-
sively inherited disease characterized by recurrent, self-limited febrile attacks with 
serositis, synovitis, and occasionally skin involvement. AA amyloidosis is the most 
serious complication of FMF and can be life-threatening. Daily colchicine is consid-
ered standard of care, and is expected to prevent attacks and amyloidosis in most 
patients. The objective of this study is to estimate the cost burden of FMF in Turkey 
from payer perspective. Methods: Delphi technique was applied to determine 
the type and the amount of resources used in FMF based on physicians views. The 
Delphi method solicits the opinion of an expert panel through a carefully designed 
questionnaire which in this case included questions on: type, frequency and dura-
tion of the health care resources used for diagnosis and treatment of the disease, 
epidemiology of the disease and colchicine resistant patients. Ten key opinion 
experts were involved in the study.The responses were analysed and discussed in 
a face to face meeting followed by consensus building steps. Unit costs of resources 
used were obtained from payer’ Reimbursement Guideline-List of Procedure Fees Per 
Service. Results: The prevalence of the disease is estimated 0.1%. 65% of patients 
are responders to colchicine treatment, 30% are partial responders and 2-5% are 
colchicine resistant. The cost of diagnosis was 549,59TL, cost of standard treatment 
was 3.233,86TL, cost of treatment for colchicine resistant patients was 69.254,32TL 
per patient. The cost of treatment of two major complications, amyloidosis and 
renal failure were estimated as 8.628,98TL and 16.120TL respectively. The annual 
total cost of the disease to the SSI was found as 547.945.305TL without complications 
and 750.921.801TL with complications. ConClusions: FMF is highly prevalent in 
Turkey and there are unmet needs for colchicine resistant patients. The burden 
of disease is increasing with long term complications and colchicine resistance.
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bACkgRound: Atypical haemolytic uraemic syndrome (aHUS) is a progressive, life-
threatening, and ultra-rare disease with an estimated prevalence of 5.5 persons 
per million in England (AGNSS in 2012). objeCtives: There is a lack of literature 
describing the economic and humanistic burden of aHUS. A patient survey was 
undertaken to evaluate the impact of aHUS on patients, their carers and society in 
the UK. Methods: aHUS patients and their carers were recruited by the UK aHUS 
Patients and Families Support Group and were asked to complete an online ques-
tionnaire. Respondents described the impact of aHUS on daily activities, work and 
out-of-pocket expenses. Results: 37 patients with aHUS completed the survey. 
23 patients were above 18 years of age (23/35). 61% of adult patients (14/23) were 
employed, 39% (9/23) were not currently in employment; of these, 33% (3/9) were 
retired. The rate of economically inactive adults among aHUS patients exceeded 
the UK national average by 20%. Based on the UK median earning (ONS 2012), an 
annual lost productivity cost of £2,650 per aHUS patient or £472 of lost tax rev-
enues was calculated. 54% (20/37) of aHUS patients had a carer, of which 82% (16/20) 
were informal carers (ie. family members). On average, carers lost 18 hours of paid 
work per week and estimated £12,190 lost productivity/£2,170 lost tax revenues per 
carer. The following out-of-pocket expenses (per patient per year) were estimated 
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is fully funded by National Health System in Portugal since 2001. Since March 2013 
Portuguese electronic prescription system became more generalized, allowing 
central monitoring and validation of medicines prescription and dispensing. This 
database only contains medicines dispensing data in ambulatory setting. TTR-
FAP anonymized patient’s utilization was requested to Administração Central do 
Sistema Saúde(ACSS). International Non-proprietary Names (INN) were extracted 
from INFARMED medicines database. Total and mean annual costs per patient are 
reported in euros. Results: Over the year 2014, a total of 70 286 electronic dispens-
ing activities were imputed to 2013 TTR-FAP anonymized patients in ACSS data-
base. The total cost with TTR-FAP medicines dispensed in ambulatory setting was 
1 612 673 € . The mean annual cost per patient was 801 € (standard deviation 1 233 
€ ). ConClusions: We can conclude that Portuguese ACSS electronic prescription 
database is a useful, relevant and accessible strategy to estimate medicines expendi-
ture trough anonymized individual patient data. Access to additional individual 
patient data such as age/gender would enhance future studies. We can estimate 
that TTR-FAP disease in Portugal accounted for 1 612 673 € total cost in ambulatory 
medicines, with a mean annual cost per patient of 801 € .
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objeCtives: To describe the hospital stays of patients with systemic lupus erythe-
matosus (SLE) in Belgium during one calendar year. Methods: All adult patients 
having ≥ 1 stay with a primary or secondary diagnosis of SLE (ICD-9-CM code 710.0) 
in 2013 were retrieved from the longitudinal IMS Hospital Disease Database (HDD; 
capturing 24% of Belgian hospital beds). All stays generated by these patients 
during the year were retrieved with their characteristics (admission type, associ-
ated diagnoses, in-hospital mortality, length of stay, drugs, procedures, costs) and 
descriptive statistics were derived (mean +/- standard deviation or [interquartile 
range]). Correlation coefficients (Pearson, Spearman) were calculated between 
age, number of stays/patient, total length of stay/patient, annual cost/patient 
and the number of organ systems involved (estimated per patient, based on the 
ICD-9-CM codes of associated diagnoses, further classified into SLE-specific organ 
systems). Results: In 2013, 434 adult SLE patients were identified (82.0% female; 
mean age 54.8 +/- 17.0 years; mean 3.0 [2-4] organ systems involved distributed 
as follows: Musculoskeletal 97.9%, Circulatory/respiratory 54.4%, Mental/Nervous 
system 38.8%, Digestive 31.8%, Renal 29.0%, Haematologic 25.0%, Skin/subcuta-
neous tissue 15.4%, Ophthalmic 6.1%. The mean annual hospitalization cost/
patient was € 8,741 [1,715-9,533]). These patients generated 939 stays (2.2 [1-2] 
stays/patient; 29.7% unplanned admissions; 56.4% full hospitalizations with mean 
length of stay 8.4 days [2-9]). The in-hospital mortality was 2.2% and the mean 
total cost/stay was € 4,069 [366-4,202]). The number of organ systems involved was 
significantly (p< 0.001) correlated to age (Pearson/Spearman: 0.40/0.38), number 
of stays/patient (0.21/0.26), total length of stay (0.57/0.59) and annual cost/patient 
(0.53/0.55). ConClusions: The analysis of real-world hospitalization data showed 
how the burden and complexity of SLE management increases as the organ sys-
tems involvements accrue. Extrapolating the HDD data to the total Belgian popu-
lation, about 1,800 SLE patients might require hospital treatments every year, 
representing a substantial burden for patients and society.
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objeCtives: A myriad of valuation techniques are used by various healthcare 
system stakeholders to appraise drugs. The objective of this evaluation was to 
develop a systematic and evidence-based approach to appraising a drug’s rela-
tive performance. We developed a multi-attribute valuation methodology taking 
into account efficacy, safety and humanistic factors to synthesize relative value 
created by pharmaceutical interventions. We report on our findings for ten onco-
logic therapies. Methods: Health Technology Assessments (HTAs), published trial 
results, and publications archived in PubMed all between 2005 – 2013 were analyzed 
to identify key value attributes. The following five attributes were considered: a) 
Overall Survival (OS), b) Progression Free Survival (PFS), c) Route of Administration, 
d) Trial Comparator, and e) Adverse events. Based on outcomes from clinical tri-
als for each of those attributes for each drug analyzed, the performance of the 10 
oncologic therapies was measured on the selected attributes. We then generated an 
aggregate score for each drug. Drugs were then compared on value score vs. cost of 
treatment to understand the value-cost relationship. Results: The multi-attribute 
analysis and scoring exercise demonstrated that drugs with more than 3 months of 
OS benefit incremental to their clinical trial comparator had higher net value scores, 
whereas PFS without a complementary increment in OS did not significantly impact 
the value score of the drug. Based on a linear model we developed, drug prices 
increased approximately $170/month ($2040/year) for each month of OS improve-
ment. Larger samples will be required to confirm this correlation. ConClusions: 
The framework may be employed to assign a value “score” for cancer drugs that 
may help stakeholders to assess value versus cost of an oncology treatment. Further 
research is needed to compare and contrast this framework with ’other’s such as 
Memorial Sloan Kettering Cancer Center’s “Drug Abacus” framework.
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in 2009: 73% of all costs, cumulatively 300.805,52 EUR (2009-2013). Total average costs 
for period of 5 years (2009-2013) per 1 patient was 48.884,01 EUR. Year-by-year aver-
age costs for 1 patient were as follows: in 2009 24.795 EUR, in 2010 4.682 EUR, in 2011 
3.273 EUR, in 2012 3.630 EUR and in 2013 12.456 EUR. Most influential cost factor was 
average hospitalization/1 patient that dramatically decreased between 2009 and 
2011 (16.651 EUR vs 2.009 EUR) and than increase between 2011 and 2013 (2.009 EUR 
vs 10.531 EUR). We also found negative significant statistical correlation between 
age of patients and costs. ConClusions: We performed first direct costs analysis 
in patients with CF in single center. More data are needed to be able to evaluate 
exact costs associated with CF treatment that should serve as solid background for 
decision making process at national level.
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objeCtives: To analyze the cost of treating invasive fungal infections (IFI) in stem cell 
transplant patients. Methods: Prospective observation cost study from the hospital 
point of view was performed in the major hematology clinic in Sofia for one year 
period. Bottom up cost analysis for the consumed health care resources and their 
cost was performed for all stem cell transplant patients. Medical resources included 
in the analysis was the clinical tests, medical devices, transplantation procedure, 
medicines, blood and blood formulating products, conditioning regime and cost of 
hospital stay. Cost of the resources was taken from the hospital tariff and insurance 
fund charges. Direct medical cost was calculated for the average transplant procedure 
and for the patients when IFI appears. Results: Every patent with hemopoietic stem 
cell transplantation is considered for highly risky for fungal infection appearing due 
to suppressed immune system. Antifungal prophylactic is obligatory for allogenic 
transplantation (n= 27) and for susceptible patients with autologues transplantation 
(n= 64). For allogenic transplantation prophylactic is performed with voriconazole and 
costs 3500 Euro. For the other patients usually fluconazole or itraconazole is used cost-
ing 1600 Euro. The total cost of allogenic transplantation from relative donor is 15000 
Euro, for allogenic transplantation from non-relative is 25000 Euro and for autologues 
transplantation is varying between 10-20 000 Euro. Despite of prophylactics 3 IFIs were 
recorded during one year period and the cost of therapy rise to 50 000 Euro mostly due 
to increase in medicines cost to 66% of total cost. ConClusions: The IFIs are twice 
increasing the average cost of hemopoietic stem cell transplantation mainly due to 
the increase in the cost of medicines to manage the infection.
PSY49
coST analYSIS of vorIconazole verSuS lIPoSomal amPhoTerIcIn B and 
caSPofungIn for PrImarY TheraPY of InvaSIve aSPergIlloSIS among 
hIgh-rISk hemaTologIc cancer PaTIenTS In SaudI araBIa
Thaqafi AA1, Xue M2, Farahat F1, Gao X2, Wafy MH3, Fahti M3, Ibrahim A3, Charbonneau C4
1NATIONAL GUARD HEALTH AFFAIRS, Riyadh, MD, USA, 2Pharmerit International, Bethesda, 
MD, USA, 3Pfizer, Riyadh, Saudi Arabia, 4Pfizer Inc, Paris, France
objeCtives: Published real-world studies suggest voriconazole may provide reduced 
length-of-stay, intravenous (IV) length-of-therapy (LOT), and costs compared to liposo-
mal amphotericin B (LAMB) and caspofungin in invasive aspergillosis (IA) patients. We 
performed a cost analysis of voriconazole versus LAMB and caspofungin as first-line 
antifungal treatment for IA among patients with prolonged neutropenia or undergo-
ing bone marrow or hematopoietic stem-cell transplantation (BMT/HSCT) from payer 
perspective in Kingdom of Saudi Arabia (KSA). Methods: A decision analytic model 
with a 6-week time horizon was constructed to estimate potential treatment cost of 
alternative interventions voriconazole, LAMB, and caspofungin. Each treatment path-
way was defined by probabilities of an event occurrence and costs (in US$) of clinical 
outcomes derived from published literature, clinical trials, and local expert opinions. 
Patients who failed first-line voriconazole were assumed to have a switch-to or add-on 
of caspofungin; patients who failed LAMB or caspofungin were assumed to have a 
switch-to or add-on of voriconazole. Base-case evaluation included drug management 
costs and additional hospitalization costs due to severe adverse events. Results: 
Based on the clinical trial treatment success rates of 52.8% for voriconazole, 50.0% for 
LAMB, and 33% for caspofungin, as well as assuming first-line 14-day IV treatment 
and 10-day oral treatment for voriconazole, 24-day IV treatment for LAMB, and 24-day 
IV treatment for caspofungin in KSA, voriconazole had a considerable lower total 
treatment cost ($7,654) than LAMB ($16,564) and caspofungin ($17,362). Cost savings 
were primarily due to the lower drug cost, higher treatment efficacy, and shorter IV 
length-of-therapy associated with voriconazole. The cost advantage of voriconazole 
persists through a full-course of the first-line treatment with voriconazole IV (24 
days in KSA), even without oral treatment. ConClusions: This study suggests that 
voriconazole is cost-saving compared to LAMB and caspofungin in the treatment of 
IA from payer perspectives in KSA.
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objeCtives: Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) is a 
rare, progressive, debilitating and life-threatening neurodegenerative disease. 
Treatment for clinical symptoms of the disease is a priority. Although a rare dis-
ease, Portugal has the largest TTR-FAP foci in the world but data on treatment 
costs is lacking. The purpose of this study is to estimate the ambulatory medicines 
costs of TTR-FAP in Portugal. Methods: TTR-FAP patient’s medicines utilization 
